Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Change in Acquisitions & Divestments (2016 - 2025)

Capricor Therapeutics (CAPR) has 12 years of Change in Acquisitions & Divestments data on record, last reported at $78.2 million in Q3 2025.

  • For Q3 2025, Change in Acquisitions & Divestments rose 257.66% year-over-year to $78.2 million; the TTM value through Sep 2025 reached $214.1 million, up 121.36%, while the annual FY2024 figure was $93.8 million, 10.33% down from the prior year.
  • Change in Acquisitions & Divestments reached $78.2 million in Q3 2025 per CAPR's latest filing, up from $76.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $78.2 million in Q3 2025 and bottomed at $14.0 million in Q2 2022.
  • Average Change in Acquisitions & Divestments over 4 years is $34.2 million, with a median of $29.1 million recorded in 2022.
  • Peak YoY movement for Change in Acquisitions & Divestments: tumbled 48.86% in 2023, then soared 257.66% in 2025.
  • A 4-year view of Change in Acquisitions & Divestments shows it stood at $38.4 million in 2022, then tumbled by 48.86% to $19.6 million in 2023, then decreased by 14.89% to $16.7 million in 2024, then surged by 367.64% to $78.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $78.2 million in Q3 2025, $76.0 million in Q2 2025, and $43.2 million in Q1 2025.